Paediatric microbial keratitis prognosis more effective with intensive drug therapy

Article

Early diagnosis, intensive drug therapy, and timely surgical intervention are all associated with the improved prognosis of paediatric microbial keratitis.

Early diagnosis, intensive drug therapy, and timely surgical intervention are all associated with the improved prognosis of paediatric microbial keratitis, states an investigation in the European Journal of Ophthalmology.

Dr Xiusheng Song et al., Department of Ophthalmology, Renmin Hospital of Wuhan University, China, studied the medical records of 80 eyes of 76 children with non-viral microbial keratitis. The outcome measures included demographic features, predisposing factors, clinical features, etiologic microorganisms, and treatment outcomes.

Of the patients studied, 76 met the inclusion criteria. It was found that the most common predisposing factor of microbial keratitis was trauma, with 39 of 80 patients presenting as culture positive. In 21 cases bacterial isolates were found and fungi was found in 19 cases.

Out of the 58 examined eyes, 50 presented with a best-corrected visual acuity of 20/200 or better at the last follow-up. The most frequent bacteria that were isolated were coagulase-negative Staphylococcus.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.